Table 3

Changes in N-QoL scores after 12 weeks treatment with prosultiamine
Question Before treatment After treatment Pvalue
Q1 Concentration 0.6 ± 1.0 0.3 ± 1.6 0.1235
Q2 Low in energy 0.9 ± 1.1 0.4 ± 0.6 0.0077
Q3 Sleep during the day 1.5 ± 1.4 1.0 ± 1.1 0.0229
Q4 Productiveness 0.7 ± 0.9 0.3 ± 0.6 0.0830
Q5 Physical activities 1.0 ± 1.2 0.5 ± 0.8 0.0505
Q6 Fluid restriction 0.8 ± 1.2 0.7 ± 0.9 0.3270
Q7 Inadequate sleep at night 1.6 ± 1.5 0.7 ± 1.0 0.0070
Q8 Disturbance of others 0.8 ± 1.9 0.5 ± 1.8 0.0277
Q9 Preoccupation with waking at night 0.6 ± 1.1 0.3 ± 0.6 0.1235
Q10 Worry over condition worsening 1.5 ± 1.5 0.8 ± 1.1 0.0032
Q11 Worried over treatment options 1.5 ± 1.6 1.0 ± 1.3 0.0303
Q12 Overall bother 1.3 ± 1.3 0.8 ± 0.8 0.0238
Q13 Overall impact on everyday life 2.6 ± 2.8 0.9 ± 1.0 0.0023
Converted overall score (Q1 to 12) 73.2 ± 21.0 85.3 ± 19.9 0.0001
Subscale scores:
Sleep/Energy (Q1 to5, 7) 74.0 ± 20.7 87.0 ± 15.0 0.0001
Bother/Concern (Q6, Q8 to12) 72.4 ± 25.7 83.7 ± 21.2 0.0028

Subjective symptoms were evaluated using the scores of the Nocturia Quality of Life (N-QoL) questionnaire [15-17]. The score ranges of each question except Q13 are from 0 to 4. The score of Q13 is from 0 to 10. Converted overall score (0–100) = 100 × total converted scores (Q1 to 12)/4 × question numbers, converted score = 4-each raw score. Subscale score (0 to 10) = 100 × total converted scores/4 × question numbers. Statistical significance was determined by the Wilcoxon signed-rank test.

Nakamura et al.

Nakamura et al. BMC Medicine 2013 11:182   doi:10.1186/1741-7015-11-182

Open Data